{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:55:01Z","timestamp":1759776901492},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.thromres.2024.03.029","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T01:53:04Z","timestamp":1712973184000},"page":"196-202","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical and economic burden of immune tolerance induction in entire patients with hemophilia A: Insights from a real-world Korean setting"],"prefix":"10.1016","volume":"237","author":[{"given":"Ah-Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Jo","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhyang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunjung","family":"Choo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Shil","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hankil","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.thromres.2024.03.029_bb0005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/asheducation-2016.1.657","article-title":"Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches","volume":"2016","author":"Meeks","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"4","key":"10.1016\/j.thromres.2024.03.029_bb0010","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ejh.13108","article-title":"The socioeconomic burden of patients affected by hemophilia with inhibitors","volume":"101","author":"D\u2019Angiolella","year":"2018","journal-title":"Eur. J. Haematol."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2024.03.029_bb0015","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.thromres.2010.10.006","article-title":"Immune tolerance induction in patients with hemophilia A","volume":"127","author":"Astermark","year":"2011","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.thromres.2024.03.029_bb0020","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jth.13331","article-title":"Gene therapy for immune tolerance induction in hemophilia with inhibitors","volume":"14","author":"Arruda","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.thromres.2024.03.029_bb0025","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia Awith inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.thromres.2024.03.029_bb0030","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/hae.13762","article-title":"The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab","volume":"25","author":"Carcao","year":"2019","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.thromres.2024.03.029_bb0035","doi-asserted-by":"crossref","first-page":"248","DOI":"10.5045\/br.2015.50.4.248","article-title":"Immune tolerance induction in patients with severe hemophilia A with inhibitors","volume":"50","author":"Ryu","year":"2015","journal-title":"Blood Res."},{"issue":"1","key":"10.1016\/j.thromres.2024.03.029_bb0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/hae.14192","article-title":"Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: a follow-up retrospective analysis","volume":"27","author":"Carcao","year":"2021","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.thromres.2024.03.029_bb0045","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4093\/dmj.2014.38.5.395","article-title":"Background and data configuration process of a nationwide population-based study using the Korean national health insurance system","volume":"38","author":"Song","year":"2014","journal-title":"Diabetes Metab. J."},{"issue":"7624","key":"10.1016\/j.thromres.2024.03.029_bb0050","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Von Elm","year":"2007","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.thromres.2024.03.029_bb0055","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2018-99-114249","article-title":"The Atlanta protocol: immune tolerance induction in pediatric patients with hemophilia A and inhibitors on emicizumab","volume":"132","author":"Batsuli","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2024.03.029_bb0060","author":"Health Insurance Review and Assessment Service"},{"issue":"1","key":"10.1016\/j.thromres.2024.03.029_bb0065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/hae.12780","article-title":"Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study)","volume":"22","author":"Rocino","year":"2016","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.thromres.2024.03.029_bb0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/hae.14431","article-title":"Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors","volume":"28","author":"Di Minno","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2024.03.029_bb0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.thromres.2023.02.016","article-title":"Low-dose immune tolerance induction therapy in severe hemophilia a children in China: starting earlier resulted in better inhibitor eradication outcomes","volume":"225","author":"Li","year":"2023","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2024.03.029_bb0080","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.blre.2018.02.003","article-title":"Review of immune tolerance induction in hemophilia A","volume":"32","author":"Schep","year":"2018","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.thromres.2024.03.029_bb0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10198-021-01339-4","article-title":"Costs and management of patients with hemophilia A in France: the Hemraude study","volume":"23","author":"Laurendeau","year":"2022","journal-title":"Eur. J. Health Econ."},{"issue":"5","key":"10.1016\/j.thromres.2024.03.029_bb0090","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood.V96.5.1698","article-title":"Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper","volume":"96","author":"Colowick","year":"2000","journal-title":"Blood"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T05:20:12Z","timestamp":1714108812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824001105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":18,"alternative-id":["S0049384824001105"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.03.029","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and economic burden of immune tolerance induction in entire patients with hemophilia A: Insights from a real-world Korean setting","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}